Induction of Hypertrophy in Human Cartilage Endplate Cells Promotes Angiogenesis and Catabolism in the Intervertebral Disc by Yeater, Taylor
Induction of Hypertrophy in Human Cartilage Endplate Cells Promotes Angiogenesis and 
Catabolism in the Intervertebral Disc 
 
Undergraduate Research Thesis 
 
Presented in partial fulfillment of the requirements for graduation with honors research 
distinction in Biomedical Engineering in the undergraduate colleges of The Ohio State 
University 
 
By 
 
Taylor Yeater 
 
The Ohio State University 
May 2017 
 
Project Advisor: Devina Purmessur, Department of Biomedical Engineering
i 
 
Abstract 
Low back pain is second only to cancer in terms of socioeconomic burden in the U.S., but 
current treatments are highly invasive and fail to target the underlying cellular mechanisms 
of intervertebral disc (IVD) degeneration. In degeneration, the cartilaginous end plate 
(CEP) becomes calcified, however the mechanisms are not well understood. In diseases 
such as osteoarthritis, a proposed mechanism is the recapitulation of developmental 
processes and we suggest that in degeneration, CEP cells undergo hypertrophic 
differentiation similar to endochondral ossification. The aim of this study was to determine 
if CEP cells can undergo hypertrophic differentiation, leading to angiogenesis. Human CEP 
cells (hCEPs) were isolated from autopsy and pellet cultured. For 21 days, pellets were 
cultured in either chondrogenic or hypertrophic (10% FBS or CHIR99021, a wnt agonist) 
media in 5% oxygen, after which samples were used for viability, histology, qRT-PCR, 
DMMB proteoglycan assay, and generation of conditioned media (CM). Soluble factors 
from CM generated after 21 days was pooled, and a HUVEC tubular formation assay ran. 
Tubular length was assessed using Image J plug in, Angiogensis Analyzer. No significant 
decreases in viability were seen in the chondrogenic control group. QRT-PCR showed a 
decrease of chondrogenic marker, COL2, in both hypertrophy groups compared to the 
chondrogenic group. Hypertrophic markers MMP13 and IHH displayed increases in the 
hypertrophy groups. Increases were also seen in the angiogenic and pain related markers, 
VEGF-A, TAC1, and NGF in the hypertrophy groups. DMMB assay and histological 
results show decreases in proteoglycans in the hypertrophy groups. HUVEC tubular 
formation assay showed that both hypertrophy groups increased the total length of tubules. 
This study sought to determine the underlying cellular mechanisms of low back pain and 
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suggests that human CEPs have the ability to undergo hypertrophic differentiation similar 
to articular chondrocytes during OA, with subsequent angiogenesis and neoinnervation, 
and may be implicated in the process of IVD degeneration. 
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Background 
Significance and problem statement 
Low back pain (LBP) is one of the most prevalent sources of socioeconomic burden, 
comparable to heart disease or diabetes (Maetzel & Li, 2002), and intervertebral disc (IVD) 
degeneration is implicated in the progression of chronic LBP (de Schepper et al., 2010; 
Freemont, 2009). It has been estimated that 7.1 million adults have activity limitation 
(Lawrence, 2008) and 70-85% of the population will experience LBP at least once during 
their lifetime (Andersson, 1999). Current interventions for acute or chronic LBP do not 
improve the economic burden, and only modestly improve clinical outcome (Maetzel & 
Li, 2002). Additionally, common interventions such as analgesics and physiotherapy do 
not address the underlying pathophysiology, but just treat the symptomatic pain. When this 
fails, highly invasive surgeries such as lumbar fusion are performed. This can lead to 
immobility and adjacent disc disease (Mannion et al., 2014). Furthermore, current 
treatments do not consider the cartilage endplate (CEP) – IVD as an organ system. Despite 
discogenic LBP being so widespread, effective and minimally invasive therapeutics based 
on the cellular changes in the IVD have yet to be developed.  
Intervertebral disc structure and function 
The intervertebral disc is comprised of three main components: the nucleus pulposus (NP), 
the annulus fibrosus (AF), and the cartilage endplate (CEP). The proteoglycan-rich NP 
imbibes fluid and serves to transmit compressive load throughout the spine, while the 
lamellar structure of collagen I in the AF transmits the tensile load of the spine. The CEP 
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contains the main structure of the disc cranially and caudally, and is the main nutritional 
pathway for the avascular IVD. These structures are shown in Figure 1 (Smith, Nerurkar, 
Choi, Harfe, & Elliott, 2011). The IVD is normally avascular, so cells rely on diffusion for 
nutrients. It has been shown that lack of oxygen or glucose will cause NP cells to become 
quiescent or die, respectively. Because of this, the IVD has a limited ability to repair itself 
from metabolic or mechanical injury (Adams & Roughley, 2006). 
 
Figure 1: Structure of intervertebral disc. Nucleus pulposus (NP), annulus fibrosis (AF) and cartilage endplate (CEP) 
are shown 
 
Intervertebral disc in degeneration 
During the progression of IVD degeneration, there is a shift in matrix remodeling with a 
net loss in extracellular matrix components. The degradation of neural inhibitory 
proteoglycans, such as aggrecan, permit neoinnervation into the IVD. It has been suggested 
that it is the nociceptive fibers, which follow neovascularization into the disc, are the source 
of LBP (Freemont, 2009). 
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In disease, the CEP becomes calcified; it has been shown that degenerative CEP 
permeability decreases 50-60%, further limiting the transport of nutrients into the disc as 
well as altering disc mechanics (DeLucca et al., 2016). Other structural changes to the CEP, 
including osteophyte formation and hypertrophy, have been deemed precursors to IVD 
degeneration (Adams & Roughley, 2006; Liu et al., 2016). Structural damage to the CEP 
and IVD has been suggested as a predisposing disease model for bone marrow lesions 
visualized as Modic changes on magnetic resonance imaging, which display high 
specificity for discogenic LBP (Dudli, Fields, Samartzis, Karppinen, & Lotz, 2016).  
Related Processes 
Related musculoskeletal diseases, such as osteoarthritis (OA), display similar pathology to 
IVD disease, and may provide insight into potential disease mechanisms. Both OA and 
IVD disease display increased matrix breakdown, inflammatory response, and 
neurovascular ingrowth (Freemont, 2009; Goldring, 2012). A proposed mechanism 
associated with pathogenesis of diseases such as OA is the recapitulation of developmental 
processes, and it has been shown that in diseases such as cancer, pulmonary fibrosis, and 
OA that pathophysiology progresses via similar mechanisms seen in development 
(Borczuk et al., 2003; Goldring, 2012; Selman, Pardo, & Kaminski, 2008).  
One such mechanism is hypertrophic differentiation and subsequent ossification of 
chondrocytes. During long bone formation, chondrocytes undergo hypertrophic 
differentiation that leads to matrix breakdown, chondrocyte apoptosis, and vascular 
ingrowth (Nishimura et al., 2012). A similar process is seen in OA chondrocytes. Pesesse 
et al showed that OA chondrocytes could undergo hypertrophic differentiation, as indicated 
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by gene expression and cellular morphology. Additionally, they showed that hypertrophic 
differentiation of OA chondrocytes could promote angiogenesis (Pesesse et al., 2013). We 
h that, in degeneration, the CEP becomes calcified via hypertrophic differentiation similar 
to OA and endochondral ossification, promoting angiogenesis and matrix catabolism in the 
IVD. 
A hypothetical model of our aims is shown below in Figure 2. The top represents the 
healthy CEP, which contains intact matrix molecules such as collagen type II and 
proteoglycans such as Aggrecan. The CEP cells here are healthy and similar to 
chondrocytes. Following the arrow of degeneration to below the image, the CEP matrix 
degrades and becomes calcified. CEP cells become hypertrophic and neovascularization 
and innervation into the disc occur. We hypothesize that through therapeutic interventions 
targeting hypertrophic differentiation, the CEP could return to a normal, healthy 
environment. 
 
Figure 2: Hypothetical model 
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Specific aims and hypotheses 
Aim 1: Determine the effects of hypertrophic differentiation on CEP cells using two known 
inducers of hypertrophy. We hypothesize that both inducers of hypertrophy will cause an 
upregulation of hypertrophic, neurogenic, and pain markers along with a decrease in 
proteoglycan content. 
Aim 2: Determine angiogenic potential of hypertrophic CEP cells by using a functional 
assay of angiogenesis. We hypothesize that conditioned media from the hypertrophic 
groups will cause an increase in total tubular length of HUVECs, indicating greater 
angiogenic potential.  
Materials and Methods 
Ethics statement 
Human autopsy specimens were obtained through the comprehensive human tissue 
network classified by the institutional review board as exempt research.  
Primary cell isolation and expansion 
Cartilage endplate cells were isolated from six human cadaveric spines. Ages of subjects 
ranged from 43 to 58; two subjects were male and four female. First, individual IVDs were 
isolated from each spine. The vertebral bodies were then scraped to remove the cartilage 
endplate tissue. Tissue was submerged in 15 ml disc cell digestion medium (see recipe 
below) containing 0.03 g protease and placed in a shaker at 37 degrees for 60 minutes. 
Media was replaced with 15 ml digestion media containing 0.0018 g collagenase II and 
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replaced on the shaker with the same settings overnight. After straining through a 70-
micrometer cell strainer to remove digested tissue and debris, cells were expanded in 
plastic culture flasks in disc cell complete medium (see recipe below). 
 Disc cell digestion medium: 4.5 g/L glucose DMEM, 100 U/ml penicillin-100 
µg/ml streptomycin, and 0.25 µg/ml amphotericin B 
Disc cell complete medium: 4.5 g/L glucose DMEM, 100 U/ml penicillin-100 
µg/ml streptomycin, 0.25 µg/ml amphotericin B, 50 µg/ml ascorbic acid, 10% FBS 
Pellet culture 
CEP cells (p. 3-4) were expanded to ~80% confluence and 1 x 106 cells were centrifuged 
at 400 rcf for 5 minutes to create a cell pellet. For 21 days, pellets were cultured in either 
chondrogenic (positive control), 10% FBS, or Wnt Agonist (CHIR99021) media in 5% O2, 
5% CO2, and 37°C with media changes every 3-4 days. 10% FBS medium was chosen 
because it has been shown to induce hypertrophic differentiation in OA chondrocytes 
(Pesesse et al., 2013), as was wnt agonist (Enochson, Stenberg, Brittberg, & Lindahl, 
2014). 
Chondrogenic medium 4.5 g/L glucose DMEM, 100 U/ml penicillin-100 µg/ml 
streptomycin, ITS (Insulin – 1 g/L; Tranferrin - 0.55 g/L ; Selenium- 0.0006 g/L ), 
20 ug/ml proline, 50 µg/ml ascorbic acid, 2 mM glutamine, 1mM sodium pyruvate, 
10-7 M dexamethasone, and 10 ng/ml TGF-β3 (added just before media change ).  
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10% FBS medium: 4.5 g/L glucose DMEM, 100 U/ml penicillin-100 mg/ml 
streptomycin, 10mM HEPES, 20 µg/ml proline, 50 µg/ml ascorbic acid, 2 mM 
glutamine, and 10% FBS.  
Basal/Wnt agonist medium: of 4.5 g/L glucose DMEM, 100 U/ml penicillin-100 
µg/ml streptomycin, 10mM HEPES, ITS (Insulin – 1 g/L; Tranferrin - 0.55 g/L; 
Selenium- 0.0006 g/L ), 20 µg/ml proline, 50 µg/ml ascorbic acid, 2 mM glutamine 
(basal media), and 0.5 uM CHIR-99021 (added just before media change to create 
wnt agonist media).  
Viability 
To determine whether culture conditions were cytotoxic after 21 days, a Calcein AM/ 
Ethidium homodimer-1viability test was performed. Pellets in 10% FBS were first rinsed 
in phosphate buffered saline solution to dilute serum esterase activity. Pellets were 
incubated for 20 minutes in serum free media with a final concentration of 2 µM calcein 
and 1 µM ethidium. A 4x fluorescent image of each pellet was taken to qualitatively 
determine relative ratio of live cells to dead cells. 
Generation of conditioned media 
Conditioned media from three (N=3) of the 21 day pellets was generated by serum starving 
samples for 24 hours in basal medium and pooling media.  Soluble factors were isolated 
from the media by centrifuging in Pall spin filters (MAP003C37) at 3000 rcf for 45 
minutes, then re-suspended in an equal volume of Medium 200 phenol red free 
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supplemented with 100 U/ml penicillin-100 µg/ml streptomycin to be used in the functional 
assay of angiogenesis.  
Histology 
After 21 days in culture, pellets (N=3) used to generate conditioned media were then kept 
in -80°C until fixing. Pellets were fixed in 10% buffered formalin for 24 hours, dehydrated, 
then imbedded in paraffin and sliced into 4 µm sections. To determine matrix production, 
the sections were deparaffinized and stained using picrosirius red (collagen) and alcian 
blue (proteoglycans) (Walter et al., 2011). 
Matrix (Proteoglycan) production 
Pellets (N=5) were kept in -80°C before biochemical analysis of proteoglycan content. 
First, samples were digested in papain. 200 µl was added to each sample and incubated in 
60°C overnight. After digest, samples were vortexed and used for dimethylmethylene blue 
(DMMB) assay to assess glycosaminoglycan (GAG) content (Luo et al., 2016). A standard 
curve was generated using known concentrations of GAG to determine GAG content in 
pellets. To determine DNA concentration, Hoescht 33258 assay was used per 
manufacturer’s instructions.  GAG concentration was normalized to DNA concentration. 
Gene expression  
To determine relative gene expression, qRT-PCR was performed on pellets from each 
group. PureLink RNA Mini Kit (Invitrogen, 12183018A) was used to isolate RNA. 
Samples from the first three subjects were lysed using 600 µl lysis buffer included with the 
RNA purification kit. 500 µl Trizol Reagent (Ambion, 15596026) was used to lyse 
9 
 
remaining samples due to poor pellet digestion with lysis buffer.  RNA content was 
quantified using Nanodrop 2000, and was stored in -80°C until complementary 
deoxyribose nucleic acid (cDNA) conversion. Samples were converted to cDNA using 
qScript XLT cDNA SuperMix (Quanta Biosciences 95161), diluted to a final concentration 
of 10 ng/reaction. Samples were stored in -20°C until qRT-PCR. Finally, qRT-PCR was 
done in duplicate using Taqman Master Mix and primers (Table 1). Gene expression was 
determined using the ΔΔCT method relative to the housekeeping gene 18s (Purmessur et 
al., 2011). 
Table 1: genes tested and role in IVD 
Target gene Role 
18s Housekeeping gene 
COL2A1 Matrix marker; indicates 
chondrogenic phenotype 
SOX9 Matrix marker; indicates 
chondrogenic phenotype 
IHH Hypertrophic marker 
MMP13 Catabolic marker; indicates 
hypertrophic phenotype 
RUNX2 Hypertrophic marker 
VEGFA Angiogenic marker 
NGF Neurogenic marker 
TAC1 Substance P; indicates pain 
 
Tubular formation assay 
A functional assay of angiogenesis utilizes the ability of Human Umbilical Vein 
Endothelial Cells (HUVEC) to spontaneously form tubular microcapillary networks on 
extracellular matrix, such as Geltrex when pro-angiogenic factors are present (Donovan, 
Brown, Bishop, & Lewis, 2001). HUVECs were expanded to 80% confluence. 100 µl of 
Geltrex was pipetted into each well of a 24-well plate, keeping the Geltrex on ice. Plates 
were then placed in 37°C for 30 minutes to allow Geltrex to gel. HUVECs were trypsinized 
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and 8.5x104 cells/well in 400 µl media were seeded in each well (N=4 wells/condition). 
Positive control was Medium 200 phenol red free + 100 U/ml penicillin-100 µg/ml 
streptomycin + low serum growth supplement. Negative control was Medium 200 phenol 
red free + 100 U/ml penicillin-100 µg/ml streptomycin. 
Statistical Analysis 
GraphPad Prism version 6 software was used to determine statistical significance. Sample 
size for each test ranged from N=4 to N=6. Kruskal Wallis nonparametric test was used 
with Dunn’s post-hoc analysis. Results were significant if P < 0.05. 
Results 
Long-term culture of hCEPs does not affect cell survival in control pellet 
culture 
To ensure cells were remaining viable throughout the 21-day study, a Calcein AM/ 
Ethidium homodimer-1 assay was performed. As can be seen qualitatively in Fig. 3, the 
chondrogenic (positive) control group showed the highest cell survival, as indicated by 
green (live cell) areas. In contrast, the 10% FBS (hypertrophic) group exhibited more cell 
death, as indicated by the red (dead) areas. The wnt agonist (hypertrophic) group displayed 
viability between the chondrogenic and the 10% FBS groups.   
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Hypertrophic differentiation of hCEPs promotes catabolism 
Images of pellets were taken after 21 days in culture to compare relative size of pellets. As 
can be seen in Figure 4, chondrogenic pellets appeared the largest. 10% FBS pellets were 
the smallest, and the wnt agonist group had a pellet size between the chondrogenic and 
10% FBS groups 
 
Picrosirius red and alcian blue staining was done to determine the matrix accumulation and 
visualize the distribution of collagen (red) and proteoglycan (blue). As can be seen in Fig 
5, the chondrogenic control group has the most proteoglycan content, as indicated by the 
Figure 3: Representative images of live/dead assay 
Figure 4: Representative images of pellet size 
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mostly blue appearance of the pellet. In the 10% hypertrophic group, proteoglycan 
presence was greatly diminished, as the pellet is mostly red. The wnt agonist pellet is also 
mostly comprised of collagen, but faint blue on the right edge of the pellet indicates some 
proteoglycan presence. 
 
Figure 5: Representative histology images. Scale = 200 µm 
 
Matrix accumulation was quantitatively assessed by 
performing a papain digest of the pellets, then 
determining GAG content through a DMMB assay. After 
normalizing to DNA content, it was seen that the 
chondrogenic control group accumulated the most 
proteoglycan. The 10% FBS hypertrophic group had 
significantly lower matrix accumulation. Again, the wnt 
agonist hypertrophic group had results between the chondrogenic and 10% FBS groups 
(Figure 6). 
Chondrogenic  10% FBS Wnt agonist 
Figure 6: Results from DMMB assay. 
Bar indicates statistical significance (P 
< 0.01) 
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Hypertrophic phenotype of hCEPs is indicated by gene expression 
After 21 days in pellet culture, cells were lysed and gene expression determined. All gene 
expression was normalized to the chondrogenic control. Values of fold change and P value 
are included in Table 2. One set of genes were matrix markers collagen type II (COL2) and 
SOX9. As can be seen in Figure 7 (matrix markers), both hypertrophic groups had 
significantly decreased COL2 production with the 10% FBS group having the largest 
difference. Interestingly, another matrix marker, SOX9 showed significant upregulation in 
the 10% FBS group. Hypertrophic markers IHh, MMP13, and Runx2 were also determined 
(Fig 7 (hypertrophic markers)). Upregulation, but not significant, of IHh was seen in both 
hypertrophic groups. The catabolic gene MMP13 showed the largest upregulation of all 
genes for both hypertrophic groups, and was significant in the 10% FBS group. Runx2, a 
transcription factor involved in IHh pathway, was upregulated in both hypertrophic groups, 
again with significance seen in the 10% FBS group.  
 
Figure 7: Gene expression of hypertrophic CEPs relative to chondrogenic control 
 
The final group of gene expression determined were neurovascular and pain markers, 
which are indicative of the diseased IVD (Fig7 (neurovascular and pain markers)). The 
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angiogenic factor, VEGF, was significantly upregulated in both hypertrophic groups. The 
neurogenic factor, NGF, was also significantly upregulated in both groups. Upregulation 
for both genes was similar between the two hypertrophic groups, unlike the trend seen in 
previous results. The pain marker TAC1, or Substance P, was upregulated in both groups, 
but this was not significant. 
Table 2: ΔΔCT values and P-values for gene expression 
 
Hypertrophic differentiation of hCEPs promotes angiogenesis 
Tubular formation of HUVEC cells was observed to determine the angiogenic potential of 
the CEP cells. Conditioned media from each cell pellet was applied to the HUVECs, and 
fluorescent images taken (Figure 8). The positive control exhibited strong tubular 
formation, with a few examples of thick tubules indicated by red arrows. The negative 
control did not form many tubules, and of those formed they were either thin or broken. 
The chondrogenic control showed similar tubular formation as the negative control, with 
many tubules being short or broken. The 10% FBS hypertrophic groups was similar to the 
positive control, and thick tubules are indicated with red arrows. Finally, the wnt agonist 
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group displayed tubular formation between the chondrogenic control and the 10% FBS 
group. 
 
Figure 8: Qualitative images of HUVEC tubular formation 
 
Because it is difficult to assess tubular formation visually, an ImageJ plug in was used to 
quantify the images. An example of a quantified image is show in Figure 9A. The results 
from the quantification are shown in Figure 9B. The only significant difference seen here 
is between the 10% FBS group and the negative control, with the 10% FBS group 
exhibiting more tubular formation. 
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Figure 9: Quanitified HUVEC tubular formation. Bar indicates significane (P < 0.01) 
 
Discussion and Conclusion 
Summary  
This study sought to characterize hypertrophic differentiation of CEP cells by using two 
factors shown to induce hypertrophy in OA chondrocytes, 10% FBS and wnt agonist. To 
characterize differentiation tests were run to examine viability, gene expression of matrix 
markers, gene expression of hypertrophic markers, and gene expression of neurovascular 
and pain markers. Downregulations were seen in matrix marker COL2 for hypertrophic 
groups, and upregulations seen in hypertrophic markers for hypertrophic groups. 
Neurovascular and pain markers also exhibited upregulations in the hypertrophic groups. 
Matrix production was assessed through histological analysis and DMMB assay, which 
both revealed decreased proteoglycan content in hypertrophic groups. To confirm 
A B 
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angiogenic potential of CEP cells, a functional assay of angiogenesis was performed via 
HUVEC tubular formation, and increased tubular formation was seen in the 10% FBS 
hypertrophic group.  
Discussion based on hypothetical model 
Hypertrophy 
The first goal of this study was to determine if CEPs could undergo hypertrophic 
differentiation. To do so, cells were cultured in medium known to induce 
hypertrophy, and gene expression evaluated. As shown in OA literature, 
hypertrophic chondrocytes will display upregulations in specific genes, including 
IHh, MMP13, and Runx2. Our culture model showed significant upregulations of 
MMP13 and Runx2 in the 10% FBS group. Though not significant, IHh, MMP13 
for the wnt agonist group, and Runx2 for the wnt agonist group all displayed 
upregulations. Sample size for gene expression was between N=3 and N=5, which 
is relatively small, and with increased sample size groups may become significant.  
Additionally, viability of pellets was assessed. The chondrogenic control group 
showed the most viability, suggesting that the 21-day culture in hypoxia did not 
affect cell survival. The hypertrophic groups, however, displayed more cell death, 
especially in the 10% FBS group. Normally this amount of cell death would be 
concerning. However, during hypertrophic differentiation, chondrocytes eventually 
undergo apoptosis to allow for matrix calcification. Because only the hypertrophic 
groups displayed this amount of cell death, it supports CEP hypertrophic 
differentiation by 10% FBS and wnt agonist. 
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These results were similar to those seen in the hypertrophic differentiation of OA 
cells, as described in Pessese et al and Enochson et al. 10% FBS was able to induce 
a hypertrophic phenotype in OA chondrocytes, and increases in hypertrophic 
markers MMP13 and Runx2 were seen (Pesesse et al., 2013). Pesesse et al were 
also able to show the morphology of the cells, and confirm cells were hypertrophic 
through increased intracellular volume. Because this study utilized high density 
pellet culture, it is difficult to determine cellular morphology. Enochson et al 
similarly showed that OA chondrocytes could become hypertrophic via a wnt 
agonist, as confirmed by hypertrophic and matrix markers (SOX9, COL2, 
MMP13). 
Previous work has shown that hypertrophic CEPs can be rescued with ligustrazine, 
which suppressed TGF-β1 expression (Liu et al., 2016). However, hypertrophic 
CEPs in Liu et al were not fully characterized as hypertrophic, but rather 
osteogenic, and endochondral ossification was not considered.  
Catabolism 
After determining CEPs could undergo hypertrophic differentiation, the effect on 
matrix catabolism by hypertrophic CEPs was explored. To do so, histological 
staining with picrosirius red and alcian blue was performed and a DMMB assay 
ran. The chondrogenic control group showed the most proteoglycan content, which 
was confirmed by detection of GAG chains via the DMMB assay. The least 
proteoglycan was seen in the 10% FBS group. Again, the wnt agonist group 
displayed results between the control and 10% FBS groups. The disappearance of 
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proteoglycan in the hypertrophic groups can be explained either by down regulation 
of matrix proteins, by upregulation of catabolic enzymes, or by a combination of 
the two. Due to the significant upregulation of the catabolic gene MMP13, it is 
likely that catabolism is involved. 
In previously described work on OA chondrocytes, similar effects were seen on 
catabolism and matrix production. Both Pesesse et al and Enochson et al showed 
increases in the catabolic gene MMP13. Additionally, Enochson et al, through 
histological analysis, showed that hypertrophic chondrocytes produced less 
proteoglycan. The difference in their study was that they were able to regain matrix 
production via GDF5, which reduced MMP13 expression. 
Angiogenesis 
The CEP is normally only thought to have a nutritional role in the IVD. It has been 
shown that the CEP calcifies in degeneration, but the effects of this have only been 
explored with relevance to metabolite transfer. The second aim of this study was to 
show that hypertrophic CEPs release factors that affect the surrounding 
environment. First, gene expression of neurovascular and pain markers was 
assessed. In both hypertrophic groups, upregulation of neurogenic marker, NGF, 
and angiogenic marker, VEGF were seen. This supports the role of the CEP in 
influencing the symptomatic IVD, which has nerve and blood vessel ingrowth. 
Gene expression is an indication of protein synthesis, but to confirm the angiogenic 
potential of hypertrophic CEPs, a functional assay of angiogenesis was performed. 
HUVECs were cultured with conditioned media generated from each condition, 
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and tubular formation assessed. Increases were seen in the 10% FBS hypertrophic 
group, further supporting angiogenesis caused by degenerate CEPs. 
Pesesse et al determined the influence of hypertrophic OA chondrocytes on 
angiogenesis. To determine angiogenic potential of the hypertrophic chondrocytes, 
they performed assays to measure adhesion, migration, and invasion of endothelial 
cells. Similar to their study, we showed that hypertrophic CEPs can influence 
angiogenesis. 
Significance and conclusion 
These results suggest that human CEPs can undergo hypertrophic differentiation similar to 
what is seen in the progression of OA. This study also supports the role of hypertrophic 
CEPs to enhance angiogenesis and pain in the degenerate IVD. Additionally, this work 
highlights a unique role for CEP hypertrophy in mechanisms underlying the pathogenesis 
of disc degeneration and low back pain, and provides a potential target for therapeutics. 
Limitations and Future Directions 
Collagen type X 
Collagen type X (COLX) is a well-known indicator of hypertrophic differentiation in 
chondrocytes (Pesesse et al., 2013). In the current study, COLX gene expression was 
determined for 3 samples, but no expression was seen (data not shown). One explanation 
is the stage of hypertrophic differentiation COLX is expressed. It has been determined that 
COLX is expressed by early hypertrophic cells (Kozhemyakina, Lassar, & Zelzer, 2015). 
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Because other factors, such as VEGFA, Runx2, and MMP13 are all upregulated during the 
late hypertrophic stage, it is likely that COLX expression was upregulated at an earlier 
timepoint. By the 21-day time point, COLX expression may have disappeared. To 
determine if protein synthesis occurred, pellets can be examined for COLX via 
immunohistochemistry. 
Chondrocyte de-differentiation 
It is known that chondrocytes and chondrocyte-like cells such as the NP dedifferentiate in 
monolayer expansion. Cells lose their chondrogenic phenotype, shown through decreased 
collagen type II and aggrecan production, even after 21 days in 3D pellet culture and 
chondrogenic media (Rosenzweig et al., 2017). Because CEPs were expanded in 
monolayer, this dedifferentiation may have occurred, affecting the matrix production in 
this study. While this is an obvious limitation, pellet culture attempts to regain the 
chondrogenic phenotype of the cells and is a commonly used technique. 
Functional assay of angiogenesis 
While the tubular formation assay is an indicator of vascularization, it may not be the best 
model to describe angiogenesis. To fully explore the angiogenic effect of hypertrophic CEP 
cells, more relevant tests should be completed. Examples of these tests include cellular 
invasion, migration, and adhesion assays, as described previously (Pesesse et al., 2013).  
Future directions 
This aims of this study were to examine the effect of hypertrophic differentiation of CEP 
cells and to confirm using a functional assay of angiogenesis, but future studies to 
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determine the mechanism are needed. To confirm that IHh is the pathway to hypertrophy 
for CEPs, we will perform receptor blocking studies and RNA interference of IHh. 
Receptor blocking will be done via cyclopamine, an antagonist for IHh (Chen, Taipale, 
Cooper, & Beachy, 2002). Small (or short) interfering RNA, also known as siRNA, will be 
used for temporary gene knockdown via messenger RNA degradation. If these methods are 
successful in abolishing hypertrophic differentiation, therapeutic agents that target IHh in 
the IVD can be explored. 
Future studies can also be used to determine the effects of hypertrophic CEPS on NP and 
AF cells. To do so, conditioned media generated from the hypertrophic CEPs can be 
introduced to the NP and AF cells. The gene expression and matrix production of these 
cells can be determined like was described in this study. Results will elucidate the role of 
the CEP-IVD interactions. Additionally, this may suggest that the CEP is more than a 
nutritional pathway for the IVD, but rather plays a role in the biochemical 
microenvironment of the IVD. 
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